Loading stock data…
PGEN
$4.08-0.08 (-1.92%)
Market ClosedLast close May 1
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Precigen, Inc. in the Healthcare sector is trading at $4.08. The stock is currently 25% below its 52-week high of $5.47, remaining 9.1% above its 200-day moving average. Technical signals show neutral RSI of 46 and bullish MACD crossover, explaining why PGEN maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.08
Potential Upside
5%
Whystock Fair Value$4.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers the...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.40B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1198.61%
Volume
Today's trading volume
1.67M
Recent News
3 Growth Stocks With High Insider Ownership Achieving 19% Revenue Growth
Over the last 7 days, the United States market has remained flat, yet it is up 29% over the past year with earnings forecast to grow by 16% annually. In this environment, identifying growth stocks with high insider ownership can be appealing as these companies often benefit from strong alignment between management and shareholders, potentially driving sustainable revenue growth.
3 Growth Companies With High Insider Ownership Expecting 28% Revenue Growth
The United States market remained flat over the last week, yet it has experienced a remarkable 29% rise over the past 12 months, with earnings forecasted to grow by 16% annually. In such an environment, growth companies with high insider ownership can be particularly appealing as they often signal confidence from those closest to the business and may be well-positioned to capitalize on expected revenue growth.
3 Growth Companies With High Insider Ownership And 25% Revenue Growth
The United States market remained flat over the last week, yet it has experienced a robust 28% rise over the past 12 months, with earnings forecasted to grow by 16% annually. In this environment, growth companies with high insider ownership and significant revenue growth can be particularly appealing as they may suggest strong confidence from those closest to the business.
Top Growth Stocks With Notable Insider Ownership
Over the last 7 days, the United States market has remained flat, but it is up 28% over the past year with earnings forecasted to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.
MiMedx (MDXG) Reports Q1 Loss, Tops Revenue Estimates
MiMedx (MDXG) delivered earnings and revenue surprises of +28.57% and +3.49%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?